110 related articles for article (PubMed ID: 10530584)
1. Rifapentine pharmacokinetics in adolescents.
Marshall JD; Abdel-Rahman S; Johnson K; Kauffman RE; Kearns GL
Pediatr Infect Dis J; 1999 Oct; 18(10):882-8. PubMed ID: 10530584
[TBL] [Abstract][Full Text] [Related]
2. Single-dose pharmacokinetics of rifapentine in women.
Keung AC; Eller MG; Weir SJ
J Pharmacokinet Biopharm; 1998 Feb; 26(1):75-85. PubMed ID: 9773393
[TBL] [Abstract][Full Text] [Related]
3. Single-dose intrapulmonary pharmacokinetics of rifapentine in normal subjects.
Conte JE; Golden JA; McQuitty M; Kipps J; Lin ET; Zurlinden E
Antimicrob Agents Chemother; 2000 Apr; 44(4):985-90. PubMed ID: 10722501
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of rifapentine at 600, 900, and 1,200 mg during once-weekly tuberculosis therapy.
Weiner M; Bock N; Peloquin CA; Burman WJ; Khan A; Vernon A; Zhao Z; Weis S; Sterling TR; Hayden K; Goldberg S;
Am J Respir Crit Care Med; 2004 Jun; 169(11):1191-7. PubMed ID: 14962821
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of rifapentine in children.
Blake MJ; Abdel-Rahman SM; Jacobs RF; Lowery NK; Sterling TR; Kearns GL
Pediatr Infect Dis J; 2006 May; 25(5):405-9. PubMed ID: 16645503
[TBL] [Abstract][Full Text] [Related]
6. Single-dose pharmacokinetics of rifapentine in elderly men.
Keung AC; Eller MG; Weir SJ
Pharm Res; 1998 Aug; 15(8):1286-91. PubMed ID: 9706063
[TBL] [Abstract][Full Text] [Related]
7. Disposition and metabolism of 14C-rifapentine in healthy volunteers.
Reith K; Keung A; Toren PC; Cheng L; Eller MG; Weir SJ
Drug Metab Dispos; 1998 Aug; 26(8):732-8. PubMed ID: 9698286
[TBL] [Abstract][Full Text] [Related]
8. The early bactericidal activities of rifampin and rifapentine in pulmonary tuberculosis.
Sirgel FA; Fourie PB; Donald PR; Padayatchi N; Rustomjee R; Levin J; Roscigno G; Norman J; McIlleron H; Mitchison DA
Am J Respir Crit Care Med; 2005 Jul; 172(1):128-35. PubMed ID: 15805182
[TBL] [Abstract][Full Text] [Related]
9. Consecutive-dose pharmacokinetics of rifapentine in patients diagnosed with pulmonary tuberculosis.
Langdon G; Wilkins JJ; Smith PJ; McIlleron H
Int J Tuberc Lung Dis; 2004 Jul; 8(7):862-7. PubMed ID: 15260278
[TBL] [Abstract][Full Text] [Related]
10. Effects of four different meal types on the population pharmacokinetics of single-dose rifapentine in healthy male volunteers.
Zvada SP; Van Der Walt JS; Smith PJ; Fourie PB; Roscigno G; Mitchison D; Simonsson US; McIlleron HM
Antimicrob Agents Chemother; 2010 Aug; 54(8):3390-4. PubMed ID: 20516273
[TBL] [Abstract][Full Text] [Related]
11. Single and multiple dose pharmacokinetics of rifapentine in man: part II.
Keung A; Eller MG; McKenzie KA; Weir SJ
Int J Tuberc Lung Dis; 1999 May; 3(5):437-44. PubMed ID: 10331734
[TBL] [Abstract][Full Text] [Related]
12. Protein binding of rifapentine and its 25-desacetyl metabolite in patients with pulmonary tuberculosis.
Egelund EF; Weiner M; Singh RP; Prihoda TJ; Gelfond JA; Derendorf H; Mac Kenzie WR; Peloquin CA
Antimicrob Agents Chemother; 2014 Aug; 58(8):4904-10. PubMed ID: 24841270
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of rifapentine in subjects seropositive for the human immunodeficiency virus: a phase I study.
Keung AC; Owens RC; Eller MG; Weir SJ; Nicolau DP; Nightingale CH
Antimicrob Agents Chemother; 1999 May; 43(5):1230-3. PubMed ID: 10223941
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of rifapentine in patients with varying degrees of hepatic dysfunction.
Keung AC; Eller MG; Weir SJ
J Clin Pharmacol; 1998 Jun; 38(6):517-24. PubMed ID: 9650541
[TBL] [Abstract][Full Text] [Related]
15. Cytokine-Mediated Systemic Adverse Drug Reactions in a Drug-Drug Interaction Study of Dolutegravir With Once-Weekly Isoniazid and Rifapentine.
Brooks KM; George JM; Pau AK; Rupert A; Mehaffy C; De P; Dobos KM; Kellogg A; McLaughlin M; McManus M; Alfaro RM; Hadigan C; Kovacs JA; Kumar P
Clin Infect Dis; 2018 Jul; 67(2):193-201. PubMed ID: 29415190
[TBL] [Abstract][Full Text] [Related]
16. Population pharmacokinetics of rifapentine and its primary desacetyl metabolite in South African tuberculosis patients.
Langdon G; Wilkins J; McFadyen L; McIlleron H; Smith P; Simonsson US
Antimicrob Agents Chemother; 2005 Nov; 49(11):4429-36. PubMed ID: 16251279
[TBL] [Abstract][Full Text] [Related]
17. Rifapentine: its role in the treatment of tuberculosis.
Temple ME; Nahata MC
Ann Pharmacother; 1999 Nov; 33(11):1203-10. PubMed ID: 10573321
[TBL] [Abstract][Full Text] [Related]
18. Population pharmacokinetics of rifapentine and desacetyl rifapentine in healthy volunteers: nonlinearities in clearance and bioavailability.
Savic RM; Lu Y; Bliven-Sizemore E; Weiner M; Nuermberger E; Burman W; Dorman SE; Dooley KE
Antimicrob Agents Chemother; 2014 Jun; 58(6):3035-42. PubMed ID: 24614383
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the pharmacokinetic interaction between repeated doses of rifapentine or rifampin and a single dose of bedaquiline in healthy adult subjects.
Winter H; Egizi E; Murray S; Erondu N; Ginsberg A; Rouse DJ; Severynse-Stevens D; Pauli E
Antimicrob Agents Chemother; 2015 Feb; 59(2):1219-24. PubMed ID: 25512422
[TBL] [Abstract][Full Text] [Related]
20. Determination of the rifamycin antibiotics rifabutin, rifampin, rifapentine and their major metabolites in human plasma via simultaneous extraction coupled with LC/MS/MS.
Winchester LC; Podany AT; Baldwin JS; Robbins BL; Fletcher CV
J Pharm Biomed Anal; 2015 Feb; 104():55-61. PubMed ID: 25481085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
